Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Minerva Neurosciences (NERV) stocks in Canada

Learn how to easily invest in Minerva Neurosciences stocks.

Minerva Neurosciences is a biotechnology business based in the US. Minerva Neurosciences stocks (NERV.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.8 – a decrease of 10.65% over the previous week. Minerva Neurosciences employs 11 staff and has a market cap (total outstanding stock value) of $31.2 million.

How to buy shares in Minerva Neurosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NERV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Minerva Neurosciences stock price (NASDAQ:NERV)

Use our graph to track the performance of NERV stocks over time.

Minerva Neurosciences shares at a glance

Information last updated 2022-01-25.
Latest market close$0.73
52-week range$0.71 - $3.69
50-day moving average $0.95
200-day moving average $1.81
Wall St. target price$7.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.84

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Minerva Neurosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Minerva Neurosciences price performance over time

Historical closes compared with the close of $0.73 from 2022-01-25

1 week (2022-01-19) -10.67%
1 month (2021-12-23) -24.34%
3 months (2021-10-26) -46.72%
6 months (2021-07-26) -61.38%
1 year (2021-01-26) -78.65%
2 years (2020-01-24) -90.89%
3 years (2019-01-25) 7.08
5 years (2017-01-26) 10.35

Is Minerva Neurosciences under- or over-valued?

Valuing Minerva Neurosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Minerva Neurosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Minerva Neurosciences's EBITDA

Minerva Neurosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.6 million.

The EBITDA is a measure of a Minerva Neurosciences's overall financial performance and is widely used to measure a its profitability.

Minerva Neurosciences financials

Gross profit TTM $19.1 million
Return on assets TTM -24.03%
Return on equity TTM -83.45%
Profit margin 0%
Book value $0.66
Market capitalisation $31.2 million

TTM: trailing 12 months

Minerva Neurosciences share dividends

We're not expecting Minerva Neurosciences to pay a dividend over the next 12 months.

Minerva Neurosciences share price volatility

Over the last 12 months, Minerva Neurosciences's shares have ranged in value from as little as $0.71 up to $3.693. A popular way to gauge a stock's volatility is its "beta".

NERV.US volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Minerva Neurosciences's is 0.886. This would suggest that Minerva Neurosciences's shares are less volatile than average (for this exchange).

Minerva Neurosciences overview

Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc.

Stocks similar to Minerva Neurosciences

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site